XNASGHSI
Market cap4mUSD
Oct 30, Last price
3.22USD
Name
Guardion Health Sciences Inc
Chart & Performance
Profile
Guardion Health Sciences, Inc., together with its subsidiaries, operates as a specialty health sciences company in the United States. It operates in two segments, Medical Foods and Nutraceuticals, and Medical Devices. The company offers Lumega-Z, a medical food that replenishes and restores the macular protective pigment; and GlaucoCetin, a vision-specific medical food to support and protect the mitochondrial function of optic nerve cells, as well as improve blood flow in the ophthalmic artery in patients with glaucoma. It also provides MapcatSF, a medical device that measures the macular pigment optical density; CSV-1000 device that offers auto-calibrated tests to ensure the correct testing luminance and contrast levels; and CSV-2000, a digital standardized contrast sensitivity testing device, as well as develops, manufactures, and sells equipment and supplies for standardized vision testing under the VectorVision name for use by eye doctors in clinical trials, real-world vision evaluation, and industrial vision testing. In addition, the company develops ImmuneSF, a nutraceutical formulation, as well as a portfolio of nutraceutical products under the NutriGuard brand. Further, it distributes medical foods products through e-commerce in an online store, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in San Diego, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 12,249 10.85% | 11,050 52.77% | 7,233 282.74% | |||||||
Cost of revenue | 16,190 | 18,371 | 17,716 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (3,942) | (7,321) | (10,483) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | 15,355 | 673 | ||||||||
Tax Rate | ||||||||||
NOPAT | (3,942) | (22,676) | (11,156) | |||||||
Net income | 158 -100.52% | (30,277) 22.36% | (24,745) 188.44% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | (5,250) | 14,268 | 33,663 | |||||||
BB yield | 77.36% | -8,772.02% | -10,980.11% | |||||||
Debt | ||||||||||
Debt current | 4 | 22 | ||||||||
Long-term debt | 4 | 30 | ||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 2,453 | 4,507 | ||||||||
Net debt | (6,360) | (10,648) | (9,037) | |||||||
Cash flow | ||||||||||
Cash from operating activities | (4,370) | (7,447) | (10,644) | |||||||
CAPEX | (4) | (6) | (75) | |||||||
Cash from investing activities | 16 | 4,990 | (31,011) | |||||||
Cash from financing activities | (5,192) | 14,268 | 37,231 | |||||||
FCF | (6,408) | (22,470) | (12,430) | |||||||
Balance | ||||||||||
Cash | 6,360 | 10,655 | 9,090 | |||||||
Long term investments | ||||||||||
Excess cash | 5,747 | 10,103 | 8,728 | |||||||
Stockholders' equity | (93,565) | (88,473) | (78,778) | |||||||
Invested Capital | 104,164 | 106,151 | 101,101 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
EV | ||||||||||
Common stock shares outstanding | 1,271 | 1,121 | 474 | |||||||
Price | 5.34 3,580.22% | 0.15 -77.58% | 0.65 55.93% | |||||||
Market cap | 6,786 4,072.16% | 163 -46.94% | 307 1,454.53% | |||||||
EV | 427 | (5,235) | (8,731) | |||||||
EBITDA | (3,922) | (6,072) | (9,576) | |||||||
EV/EBITDA | 0.86 | 0.91 | ||||||||
Interest | 15,355 | |||||||||
Interest/NOPBT |